Your browser doesn't support javascript.
loading
Epidemiologic Features of Recovery From SARS-CoV-2 Infection.
Oelsner, Elizabeth C; Sun, Yifei; Balte, Pallavi P; Allen, Norrina B; Andrews, Howard; Carson, April; Cole, Shelley A; Coresh, Josef; Couper, David; Cushman, Mary; Daviglus, Martha; Demmer, Ryan T; Elkind, Mitchell S V; Gallo, Linda C; Gutierrez, Jose D; Howard, Virginia J; Isasi, Carmen R; Judd, Suzanne E; Kanaya, Alka M; Kandula, Namratha R; Kaplan, Robert C; Kinney, Gregory L; Kucharska-Newton, Anna M; Lackland, Daniel T; Lee, Joyce S; Make, Barry J; Min, Yuan-I; Murabito, Joanne M; Norwood, Arnita F; Ortega, Victor E; Pettee Gabriel, Kelley; Psaty, Bruce M; Regan, Elizabeth A; Sotres-Alvarez, Daniela; Schwartz, David; Shikany, James M; Thyagarajan, Bharat; Tracy, Russell P; Umans, Jason G; Vasan, Ramachandran S; Wenzel, Sally E; Woodruff, Prescott G; Xanthakis, Vanessa; Zhang, Ying; Post, Wendy S.
Affiliation
  • Oelsner EC; Division of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
  • Sun Y; Department of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York.
  • Balte PP; Division of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
  • Allen NB; Center for Epidemiology and Population Health, Northwestern Feinberg School of Medicine, Chicago, Illinois.
  • Andrews H; Department of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York.
  • Carson A; Department of Epidemiology, School of Public Health, University of Alabama at Birmingham.
  • Cole SA; Texas Biomed, San Antonio, Texas.
  • Coresh J; Departments of Medicine and Public Health, NYU Grossman School of Medicine, New York, New York.
  • Couper D; Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina, Chapel Hill.
  • Cushman M; Division of Hematology/Oncology, Department of Medicine, Larner School of Medicine, University of Vermont, Burlington.
  • Daviglus M; Institute for Minority Health Research, University of Illinois College of Medicine, Chicago.
  • Demmer RT; Division of Epidemiology, Department of Quantitative Health Sciences, College of Medicine and Science, Mayo Clinic, Rochester, Minnesota.
  • Elkind MSV; Department of Neurology, Columbia University Irving Medical Center, New York, New York.
  • Gallo LC; American Heart Association, Dallas, Texas.
  • Gutierrez JD; Department of Psychology, San Diego State University, California.
  • Howard VJ; Department of Neurology, Columbia University Irving Medical Center, New York, New York.
  • Isasi CR; Department of Epidemiology, School of Public Health, University of Alabama at Birmingham.
  • Judd SE; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
  • Kanaya AM; Department of Epidemiology, School of Public Health, University of Alabama at Birmingham.
  • Kandula NR; Departments of Medicine, Epidemiology, and Biostatistics, University of California, San Francisco.
  • Kaplan RC; Center for Epidemiology and Population Health, Northwestern Feinberg School of Medicine, Chicago, Illinois.
  • Kinney GL; Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, Illinois.
  • Kucharska-Newton AM; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
  • Lackland DT; Department of Epidemiology, University of Colorado Denver.
  • Lee JS; Department of Epidemiology and Environmental Health, University of Kentucky, Lexington.
  • Make BJ; Department of Neurology, Medical University of South Carolina, Charleston.
  • Min YI; Division of Pulmonary and Critical Care, Department of Medicine, University of Colorado, Aurora.
  • Murabito JM; Division of Pulmonary, Critical Care and Sleep, Department of Medicine, National Jewish Health, Denver, Colorado.
  • Norwood AF; Department of Medicine, University of Mississippi Medical Center, Jackson.
  • Ortega VE; Department of Medicine, Boston University, Boston, Massachusetts.
  • Pettee Gabriel K; Department of Medicine, University of Mississippi Medical Center, Jackson.
  • Psaty BM; Division of Pulmonary Medicine, Department of Medicine, Mayo Clinic, Phoenix, Arizona.
  • Regan EA; Department of Epidemiology, School of Public Health, University of Alabama at Birmingham.
  • Sotres-Alvarez D; Departments of Epidemiology and Medicine, University of Washington, Seattle.
  • Schwartz D; Division of Rheumatology, Department of Medicine, National Jewish Health, Denver, Colorado.
  • Shikany JM; Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina, Chapel Hill.
  • Thyagarajan B; Division of Pulmonary and Critical Care, Department of Medicine, University of Colorado, Aurora.
  • Tracy RP; Division of Preventive Medicine, Heersink School of Medicine, University of Alabama at Birmingham.
  • Umans JG; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis.
  • Vasan RS; Department of Pathology and Laboratory Medicine, University of Vermont, Burlington.
  • Wenzel SE; MedStar Health Research Institute, School of Medicine, Georgetown University, Washington, District of Columbia.
  • Woodruff PG; School of Public Health, University of Texas School of Public Health San Antonio.
  • Xanthakis V; Department of Pulmonary, Allergy and Critical Care, Department of Medicine, University of Pittsburgh, Pennsylvania.
  • Zhang Y; Divison of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco.
  • Post WS; Section of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
JAMA Netw Open ; 7(6): e2417440, 2024 Jun 03.
Article in En | MEDLINE | ID: mdl-38884994
ABSTRACT
Importance Persistent symptoms and disability following SARS-CoV-2 infection, known as post-COVID-19 condition or "long COVID," are frequently reported and pose a substantial personal and societal burden.

Objective:

To determine time to recovery following SARS-CoV-2 infection and identify factors associated with recovery by 90 days. Design, Setting, and

Participants:

For this prospective cohort study, standardized ascertainment of SARS-CoV-2 infection was conducted starting in April 1, 2020, across 14 ongoing National Institutes of Health-funded cohorts that have enrolled and followed participants since 1971. This report includes data collected through February 28, 2023, on adults aged 18 years or older with self-reported SARS-CoV-2 infection. Exposure Preinfection health conditions and lifestyle factors assessed before and during the pandemic via prepandemic examinations and pandemic-era questionnaires. Main Outcomes and

Measures:

Probability of nonrecovery by 90 days and restricted mean recovery times were estimated using Kaplan-Meier curves, and Cox proportional hazards regression was performed to assess multivariable-adjusted associations with recovery by 90 days.

Results:

Of 4708 participants with self-reported SARS-CoV-2 infection (mean [SD] age, 61.3 [13.8] years; 2952 women [62.7%]), an estimated 22.5% (95% CI, 21.2%-23.7%) did not recover by 90 days post infection. Median (IQR) time to recovery was 20 (8-75) days. By 90 days post infection, there were significant differences in restricted mean recovery time according to sociodemographic, clinical, and lifestyle characteristics, particularly by acute infection severity (outpatient vs critical hospitalization, 32.9 days [95% CI, 31.9-33.9 days] vs 57.6 days [95% CI, 51.9-63.3 days]; log-rank P < .001). Recovery by 90 days post infection was associated with vaccination prior to infection (hazard ratio [HR], 1.30; 95% CI, 1.11-1.51) and infection during the sixth (Omicron variant) vs first wave (HR, 1.25; 95% CI, 1.06-1.49). These associations were mediated by reduced severity of acute infection (33.4% and 17.6%, respectively). Recovery was unfavorably associated with female sex (HR, 0.85; 95% CI, 0.79-0.92) and prepandemic clinical cardiovascular disease (HR, 0.84; 95% CI, 0.71-0.99). No significant multivariable-adjusted associations were observed for age, educational attainment, smoking history, obesity, diabetes, chronic kidney disease, asthma, chronic obstructive pulmonary disease, or elevated depressive symptoms. Results were similar for reinfections. Conclusions and Relevance In this cohort study, more than 1 in 5 adults did not recover within 3 months of SARS-CoV-2 infection. Recovery within 3 months was less likely in women and those with preexisting cardiovascular disease and more likely in those with COVID-19 vaccination or infection during the Omicron variant wave.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: JAMA Netw Open Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: JAMA Netw Open Year: 2024 Document type: Article
...